Compare Novo Nordisk A/S (NVO) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Novo Nordisk A/S trades at $46.11 (market cap $207.85B), while First Trust NASDAQ 100 Technology Index Fund trades at $320.7. The key difference: Novo Nordisk A/S pays a 3.81% dividend while First Trust NASDAQ 100 Technology Index Fund pays none, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | QTEC | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $335.74 |
52-Week Low | $35.29 | $207.03 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
QTEC trades at $320.61, up 1.51% today, with a bullish technical signal driven by strong moving average alignment. The ETF, tracking NASDAQ-100 technology stocks, lacks disclosed fundamental ratios but benefits from broad tech sector exposure. Recent news highlights its role in technology equity access, with a dividend scheduled for June 2026.
Outlook remains tied to technology sector performance, offering growth potential amid innovation trends. Risks include market volatility and sector concentration. Analyst sentiment is positive, but investors should weigh tech cyclicality against long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
